Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe

Esther Kissling, Marc Rondy, I-MOVE/I-MOVE+ study team (incl. G.Gefenaite), Giedre Gefenaite (medarbetare)

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

We measured early 2016/17 season influenza vaccine effectiveness (IVE) against influenza A(H3N2) in Europe using multicentre case control studies at primary care and hospital levels. IVE at primary care level was 44.1%, 46.9% and 23.4% among 0–14, 15–64 and ≥ 65 year-olds, and 25.7% in the influenza vaccination target group. At hospital level, IVE was 2.5%, 7.9% and 2.4% among ≥ 65, 65–79 and ≥ 80 year-olds. As in previous seasons, we observed suboptimal IVE against influenza A(H3N2).
Originalspråkengelska
Sidor (från-till)1-9
TidskriftEurosurveillance
Volym22
Nummer7
DOI
StatusPublished - 2017 feb. 16
Externt publiceradJa

Fingeravtryck

Utforska forskningsämnen för ”Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här